Cargando…
Can ketogenic dietary interventions slow disease progression in ADPKD: what we know and what we don't
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease leading to kidney failure. To date, there is no cure for the disease although there is one approved disease-modifying therapy: tolvaptan. In this context, a common question that ADPKD patients ask in cli...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9155227/ https://www.ncbi.nlm.nih.gov/pubmed/35664267 http://dx.doi.org/10.1093/ckj/sfac103 |
_version_ | 1784718198530113536 |
---|---|
author | Ong, Albert C M Torra, Roser |
author_facet | Ong, Albert C M Torra, Roser |
author_sort | Ong, Albert C M |
collection | PubMed |
description | Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease leading to kidney failure. To date, there is no cure for the disease although there is one approved disease-modifying therapy: tolvaptan. In this context, a common question that ADPKD patients ask in clinical practice is whether there is anything they can do to slow their disease by modifying their diet or lifestyle. Recent evidence from experimental PKD models has shown the potential benefits of caloric restriction, high water intake and especially ketogenic diets in preserving kidney function. Whether these benefits are translatable to humans remains unknown. In this issue of CKJ, Strubl et al. report results of a self-enrolled survey of autosomal dominant polycystic kidney disease (ADPKD) patients who have self-administered a ketogenic diet [1]. These results provide interesting insights into the tolerability, potential benefits and harms of such an intervention that could inform a future clinical trial. |
format | Online Article Text |
id | pubmed-9155227 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-91552272022-06-04 Can ketogenic dietary interventions slow disease progression in ADPKD: what we know and what we don't Ong, Albert C M Torra, Roser Clin Kidney J Editorial Comment Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease leading to kidney failure. To date, there is no cure for the disease although there is one approved disease-modifying therapy: tolvaptan. In this context, a common question that ADPKD patients ask in clinical practice is whether there is anything they can do to slow their disease by modifying their diet or lifestyle. Recent evidence from experimental PKD models has shown the potential benefits of caloric restriction, high water intake and especially ketogenic diets in preserving kidney function. Whether these benefits are translatable to humans remains unknown. In this issue of CKJ, Strubl et al. report results of a self-enrolled survey of autosomal dominant polycystic kidney disease (ADPKD) patients who have self-administered a ketogenic diet [1]. These results provide interesting insights into the tolerability, potential benefits and harms of such an intervention that could inform a future clinical trial. Oxford University Press 2022-04-21 /pmc/articles/PMC9155227/ /pubmed/35664267 http://dx.doi.org/10.1093/ckj/sfac103 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the ERA. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Editorial Comment Ong, Albert C M Torra, Roser Can ketogenic dietary interventions slow disease progression in ADPKD: what we know and what we don't |
title | Can ketogenic dietary interventions slow disease progression in ADPKD: what we know and what we don't |
title_full | Can ketogenic dietary interventions slow disease progression in ADPKD: what we know and what we don't |
title_fullStr | Can ketogenic dietary interventions slow disease progression in ADPKD: what we know and what we don't |
title_full_unstemmed | Can ketogenic dietary interventions slow disease progression in ADPKD: what we know and what we don't |
title_short | Can ketogenic dietary interventions slow disease progression in ADPKD: what we know and what we don't |
title_sort | can ketogenic dietary interventions slow disease progression in adpkd: what we know and what we don't |
topic | Editorial Comment |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9155227/ https://www.ncbi.nlm.nih.gov/pubmed/35664267 http://dx.doi.org/10.1093/ckj/sfac103 |
work_keys_str_mv | AT ongalbertcm canketogenicdietaryinterventionsslowdiseaseprogressioninadpkdwhatweknowandwhatwedont AT torraroser canketogenicdietaryinterventionsslowdiseaseprogressioninadpkdwhatweknowandwhatwedont |